Sinopharm Group Co. Ltd. (OTCMKTS:SHTDY – Get Free Report) was the recipient of a large decline in short interest in the month of May. As of May 15th, there was short interest totaling 11,536 shares, a decline of 72.8% from the April 30th total of 42,380 shares. Based on an average daily trading volume, of 163,961 shares, the days-to-cover ratio is presently 0.1 days.
Sinopharm Group Stock Down 0.3%
SHTDY traded down $0.03 during midday trading on Friday, hitting $10.78. 21,043 shares of the company were exchanged, compared to its average volume of 61,850. Sinopharm Group has a 1-year low of $10.57 and a 1-year high of $14.87. The firm’s 50 day moving average price is $12.37 and its 200-day moving average price is $12.91.
About Sinopharm Group
Sinopharm Group Co, Ltd. (OTCMKTS:SHTDY) is one of China’s largest integrated healthcare companies and an indirect subsidiary of the state-owned China National Pharmaceutical Group Co, Ltd. The company operates through two primary segments—pharmaceutical distribution and retail pharmacy—offering comprehensive supply chain solutions that span procurement, storage, transportation and sales of medical products. With a broad portfolio that includes prescription drugs, over-the counter medicines, medical devices and consumables, Sinopharm serves hospitals, clinics, retail pharmacies and other healthcare institutions across mainland China.
In its distribution business, Sinopharm leverages an extensive logistics network, comprising hundreds of distribution centers and thousands of delivery vehicles, to ensure timely delivery of pharmaceuticals under stringent temperature-controlled conditions.
Featured Stories
- Five stocks we like better than Sinopharm Group
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
- Palomar’s High-Risk Insurance Strategy Is Paying Off Big
Receive News & Ratings for Sinopharm Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sinopharm Group and related companies with MarketBeat.com's FREE daily email newsletter.
